Cannara BiotechLOVFF +5.52%83 Current Ratio is 3.06 as of Feb. 2026, which is 17% above its 10-year median of 2.62. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Cannara Biotech ranks better than 68.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cannara Biotech's current ratio for the quarter that ended in Feb. 2026 was 3.06.
Cannara Biotech has a current ratio of 3.06. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Cannara Biotech's Current Ratio or its related term are showing as below:
LOVFF'
s Current Ratio Range Over the Past 10 Years
Min: 0.97 Med: 2.62 Max: 11.59
Current: 3.06
During the past 8 years, Cannara Biotech's highest Current Ratio was 11.59. The lowest was 0.97. And the median was 2.62.
LOVFF's Current Ratio is ranked better than 68.04% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs LOVFF: 3.06
Cannara Biotech (OTCPK:LOVFF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Cannara Biotech Current Ratio Related Terms
Cannara Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a Current Ratio of 3.06 as of Feb. 2026. This is 17% above median its historical median of 2.62. Over the past decade, Cannara Biotech's Current Ratio has ranged from 0.97 to 11.59. According to the industry distribution chart, Cannara Biotech ranks #318 out of 995 companies in the Drug Manufacturers industry, placing it in the top 32%.
Is Cannara Biotech's Current Ratio too high?
Cannara Biotech's current Current Ratio of 3.06 is 17% above median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 11.59. The Drug Manufacturers industry median Current Ratio is 2.00. Cannara Biotech's value of 3.06 is 53% above this industry median. Based on the distribution chart, Cannara Biotech ranks #318 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #318 out of 995 companies for Current Ratio. This puts Cannara Biotech in the upper half of its industry. The industry median Current Ratio is 2.00. Cannara Biotech's value of 3.06 is 53% above this benchmark. Historically, Cannara Biotech's own Current Ratio has ranged from 0.97 to 11.59 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 2.00, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Current Ratio of 3.06 is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Current Ratio is 3.06, which is 17% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current Current Ratio is 3.06, which is 17% above median its 10-year median of 2.62 and 53% above the Drug Manufacturers industry median of 2.00. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Current Ratio is 3.06 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
Current Ratio: 3.06 (17% above median its 10-year median of 2.62)
GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
Industry Position: 53% above the Drug Manufacturers median (#318 of 995)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
